The Immune Response Corp., Carlsbad, Calif., was granted a patent,No. 648753, titled "Vaccination and Methods Against DiseasesResulting from Pathogenic Responses by Specific T Cell Populations"from the Australian Industrial Property Organization. It relates to theautoimmune disease technology developed by the company and claimscompositions and methods for the prevention or treatment of certainautoimmune diseases. Acusphere Inc., Wellesey, Mass., was issued patent No. 5,308,701,"Ionically Cross-Linked Polymeric Microcapsules," which representsbroad composition claims on the company's core microencapsulationtechnology. The patent claims microcapsules made for a variety ofsynthetic polymers. North American Vaccine Inc., Beltsville, Md., announced theissuance of a patent for the use of type III streptococcal polysaccharidein vaccine applications. North American said it was licensed the patentby Harvard University and Brigham and Women's Hospital. DNA Plant Technology Corp., Cinnaminson, N.J., was issued patentNo. 5,290,687 covering all plants genetically engineered to expresshigher levels of chitinase, an enzyme involved in plant resistance tofungal diseases. Vyrex Corp., La Jolla, Calif., was assigned patent No. 5,308,874 forvaporizable antioxidants. Genelabs Technology Inc., Redwood City, Calif., received patent No.5,306,619 covering its Merlin assay, developed for the detection andcharacterization of sequence-specific DNA-binding molecules. Calgene, Davis, Calif., was granted a European patent (EP 255 378B1) covering all seed-specific promoters and their uses in all crops,excepting a bean phaseolin promoter. One such promoter, napin, is thesubject of notice of allowance in the U.S. Calgene also was issued U.S.patent No. 5,304,481 with claims covering lauroyl-ACP thioesteraseproteins for any plant source.

(c) 1997 American Health Consultants. All rights reserved.